Literature DB >> 16720934

Drug induced arousal from the permanent vegetative state.

Ralf Clauss1, Wally Nel.   

Abstract

BACKGROUND: Zolpidem is an omega 1 specific indirect GABA agonist that is used for insomnia, but may have efficacy in brain damage. The long term efficacy of zolpidem in the permanent vegetative state is described in three patients.
METHOD: Two motor vehicle accident patients and one near drowning patient, all of them in the permanent vegetative state for at least three years, were rated according to the Glasgow Coma and Rancho Los Amigos scale before and after zolpidem application. Long term response to daily application of this drug was monitored for 3-6 years.
RESULTS: All patients were aroused transiently every morning after zolpidem. Glasgow Coma Scale scores ranged from 6-9/15 before to 10-15/15 after zolpidem. Rancho Los Amigos Cognitive scores ranged from I-II before to V-VII afterward. Drug efficacy did not decrease and there were no long term side effects after 3-6 years daily use.
CONCLUSION: Zolpidem appears an effective drug to restore brain function to some patients in the permanent vegetative state.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720934

Source DB:  PubMed          Journal:  NeuroRehabilitation        ISSN: 1053-8135            Impact factor:   2.138


  21 in total

Review 1.  The vegetative and minimally conscious states: a review of the literature and preliminary survey of prevalence in Ireland.

Authors:  M Ní Lochlainn; S Gubbins; S Connolly; R B Reilly
Journal:  Ir J Med Sci       Date:  2012-04-24       Impact factor: 1.568

Review 2.  Intrinsic brain activity in altered states of consciousness: how conscious is the default mode of brain function?

Authors:  M Boly; C Phillips; L Tshibanda; A Vanhaudenhuyse; M Schabus; T T Dang-Vu; G Moonen; R Hustinx; P Maquet; S Laureys
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

Review 3.  Pharmacotherapy for disorders of consciousness: are 'awakening' drugs really a possibility?

Authors:  Rosella Ciurleo; Placido Bramanti; Rocco Salvatore Calabrò
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

4.  GABAA receptor deficits predict recovery in patients with disorders of consciousness: A preliminary multimodal [(11) C]Flumazenil PET and fMRI study.

Authors:  Pengmin Qin; Xuehai Wu; Niall W Duncan; Weiqi Bao; Weijun Tang; Zhengwei Zhang; Jin Hu; Yi Jin; Xing Wu; Liang Gao; Lu Lu; Yihui Guan; Timothy Lane; Zirui Huang; Yelena G Bodien; Joseph T Giacino; Ying Mao; Georg Northoff
Journal:  Hum Brain Mapp       Date:  2015-07-03       Impact factor: 5.038

5.  Persons and evidence for death: A reply to Bulzacchelli.

Authors:  Stephen Napier
Journal:  Linacre Q       Date:  2013-02

Review 6.  The Effectiveness of Zolpidem for the Treatment of Disorders of Consciousness.

Authors:  Calvin Tucker; Kirsten Sandhu
Journal:  Neurocrit Care       Date:  2016-06       Impact factor: 3.210

Review 7.  Awakenings and awareness recovery in disorders of consciousness: is there a role for drugs?

Authors:  Francesca Pistoia; Elisa Mura; Stefano Govoni; Massimo Fini; Marco Sarà
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

Review 8.  Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem.

Authors:  Romy Hoque; Andrew L Chesson
Journal:  J Clin Sleep Med       Date:  2009-10-15       Impact factor: 4.062

Review 9.  Disorders of consciousness after acquired brain injury: the state of the science.

Authors:  Joseph T Giacino; Joseph J Fins; Steven Laureys; Nicholas D Schiff
Journal:  Nat Rev Neurol       Date:  2014-01-28       Impact factor: 42.937

10.  Neuroimaging and the withdrawal of life-sustaining treatment from patients in vegetative state.

Authors:  Loane Skene; Dominic Wilkinson; Guy Kahane; Julian Savulescu
Journal:  Med Law Rev       Date:  2009-05-07       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.